Long-Term Evaluation of BIIB067 (Tofersen)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03070119

Recruitment Status : Active, not recruiting

First Posted : March 3, 2017

Last Update Posted : May 22, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Ionis Pharmaceuticals, Inc.

Information provided by (Responsible Party):

Biogen

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	June 13, 2024
Estimated Study Completion Date :	June 13, 2024

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chio A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705.

To Top